[DOI] [PubMed] [Google Scholar] 211.Shibuya K, Ji X, Pfoh ER, et al
Na ausncia de ensaios clnicos de fase I/II/III concludos e publicados, impossvel traar um perfil completo dos efeitos adversos potenciais em humanos
Scores on the Three-Factor Eating Questionnaire (TFEQ-R18) improved in all treatment groups, with Cagrilintide producing greater improvements than placebo in specific domains: cognitive restraint, notably at 1.2 mg and 4.5 mg, emotional eating notably at 0.3 mg and 2.4 mg, and uncontrolled eating notably at 1.24.5 mg
pH dependent release studies displayed that the accumulative release of the DOX was increased with decrease in pH, where ~63, 16, 5 and 1.7% drug release was observed at pH 4.5, 5.5, 6.5, and 7.4, respectively
Regular medical supervision is essential to ensure safe use and to adjust treatment as needed
Electrolyte balance is important for heart rhythm and blood pressure